Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response

BACKGROUND/AIMS: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. METHODS:...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Mol Hepatol
Главные авторы: Woo, Hyun Young, Park, Jun Yong, Bae, Si Hyun, Kim, Chang Wook, Jang, Jae Young, Tak, Won Young, Kim, Dong Joon, Kim, In Hee, Heo, Jeong, Ahn, Sang Hoon
Формат: Artigo
Язык:Inglês
Опубликовано: The Korean Association for the Study of the Liver 2020
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7364362/
https://ncbi.nlm.nih.gov/pubmed/32460460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2019.0044n
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы